Employees: 2,840
Size Shanghai Forest Cabin Cosmetics (2657.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $1.04B, the 575th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$58.25 on 18 Nov 2026.
Performance Over six months the shares gained 15.5%, against +4.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 73.6% over the last twelve months (peer median +9.6%); the operating margin is 17.8% (peer median 8.6%).
Valuation It trades at 11.8× forward earnings against a peer median of 19.0× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +49%, so the hurdle is -38 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 54.2 points above its cost of capital (16.3% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.24B | HK$2.66B | HK$1.31B | HK$890M | HK$804M |
| Revenue growth | — | +103% | +47% | +11% | — |
| Gross profit | HK$2.65B | HK$2.18B | HK$996M | HK$636M | HK$532M |
| EBITDA | HK$705M | HK$555M | HK$307M | HK$183M | HK$50.0M |
| Net income | HK$487M | HK$391M | HK$203M | HK$93.4M | -HK$6.83M |
| Free cash flow | HK$570M | HK$362M | HK$223M | HK$138M | -HK$21.6M |
| Capital expenditure | HK$87.0M | HK$84.5M | HK$97.9M | HK$102M | HK$98.3M |
| Total debt | n/a | HK$171M | HK$137M | HK$77.2M | HK$46.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2657.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.1% | -3.5% | 6th highest of 21 |
| 6-month return | +15.5% | +4.3% | 7th highest of 21 |
| Distance from 52-week high | -39.3% | -30.7% | 6th lowest of 21 |
| Revenue growth (TTM) | +73.6% | +9.6% | highest of 21 |
| Operating margin | 17.8% | 8.6% | 5th highest of 21 |
| Forward P/E | 11.8× | 19.0× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 11.3% | 4.3% | 7th most demanding of 18 |
| Growth delivered (Del g) | +49.0% | +8.9% | 2nd highest of 18 |
| Hurdle (Req g minus delivered) | -37.7 pp | -4.4 pp | 2nd least demanding of 18 |
| ROIC minus cost of capital | +54.2 pp | +4.7 pp | 2nd highest of 21 |
| EV / EBITDA | 9.1× | 10.3× | 5th cheapest of 11 |
| Net debt / EBITDA | -2.5× | -0.9× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.04B | +15% | +74% | 18% | 11.8× | 11.3% | +49.0% |
| Noevir 4928.T | Japan | $978M | +7% | -3% | 28% | 20.4× | -12.8% | +4.1% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $933M | +56% | +24% | 5% | 52.5× | 28.5% | +0.8% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| Runben Biotechnology 603193.SS | China | $918M | -30% | +13% | 21% | 18.5× | 1.5% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $912M | +13% | +10% | 11% | 27.9× | 3.7% | +10.8% |
| Cosmecca Korea 241710.KS | South Korea | $847M | +23% | +42% | 12% | 16.3× | n/a | n/a |
| Galaxy Surfactants GALAXYSURF.NS | India | $845M | +22% | +30% | 9% | 17.6× | 18.5% | +13.7% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| SYoung 300740.SZ | China | $816M | -48% | +14% | 3% | 33.4× | 14.0% | +6.1% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Jyothy Labs JYOTHYLAB.NS | India | $762M | -9% | +5% | 8% | 40.8× | 34.5% | +8.9% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Milbon 4919.T | Japan | $743M | +48% | +8% | 14% | 25.7× | -3.3% | +8.2% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $726M | -18% | +10% | 6% | 17.7× | 4.4% | +7.7% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |